Text Size

Vestibular System in Migrainous Vertigo Patients

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
Sorlandet Hospital HF
Information provided by:
University of Bergen
ClinicalTrials.gov Identifier:
NCT00901953
First received: May 12, 2009
Last updated: May 14, 2009
Last verified: May 2009
History of Changes
  Purpose

Do migrainous vertigo patients have more pathology in their vestibular system than migraine patients without vertigo?

The aim of this study is to compare the vestibular system of migraine patients with and without vertigo in the symptom-free period by vestibular function tests, videonystagmography, vestibular evoked myogenic potentials, and subjective visual vertical.


Condition
Migraine Disorders
Migraine Variant
Episodic Recurrent Vertigo

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Do Migrainous Vertigo Patients Have More Hypersensitivity in Their Vestibular System Than Migraine Patients Without Vertigo?

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Bergen:

Primary Outcome Measures:
  • Differences in vestibular function [ Time Frame: Symptomfree interval ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Differences in hypersensitivity [ Time Frame: Symptomfree interval ] [ Designated as safety issue: No ]

Estimated Enrollment: 65
Study Start Date: May 2007
Estimated Study Completion Date: September 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
migrainous vertigo
2
migraine without vertigo

  Eligibility

Ages Eligible for Study:   16 Years to 61 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Migraine patients: primary care clinic

Migrainous vertigo patients: Neurological outpatients clinic, Sorlandet Hospital HF, Kristiansand and Spesialistsenteret, Tollbodgata 4, Kristiansand.

Criteria

Inclusion Criteria:

  • migraine according to IHS criteria
  • migrainous vertigo according to the Neuhauser-criteria

Exclusion Criteria:

  • no history of other neurological, vestibular, opthalmologic and ENT disorders
  • no medications that could possibly influence test results
  • intact hearing measured by audiometry
  • pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00901953

Locations
Norway
Dept. of neurology, Sørlandet Hospital HF
Kristiansand, Norway, 4604
Sponsors and Collaborators
University of Bergen
Sorlandet Hospital HF
Investigators
Principal Investigator: Åse Mygland, PhD Institute of clinical medicine, university of Bergen, Norway
  More Information

No publications provided

Responsible Party: Marion Ingeborg Boldingh, Departement of Neurology, Sørlandet Hospital HF , Kristiansand, Norway
ClinicalTrials.gov Identifier: NCT00901953     History of Changes
Other Study ID Numbers: 2.2006.3376
Study First Received: May 12, 2009
Last Updated: May 14, 2009
Health Authority: Norway: Norwegian Social Science Data Services
Norway:National Committee for Medical and Health Research Ethics

Keywords provided by University of Bergen:
migraine
migrainous vertigo
vestibular evoked myogenic potentials
vestibular function test
vestibular disorders

Additional relevant MeSH terms:
Migraine Disorders
Vertigo
Dizziness
Vestibular Neuronitis
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vestibular Diseases
 Labyrinth Diseases
Ear Diseases
Otorhinolaryngologic Diseases
Neurologic Manifestations
Signs and Symptoms
Sensation Disorders
Vestibulocochlear Nerve Diseases
Retrocochlear Diseases
Cranial Nerve Diseases

ClinicalTrials.gov processed this record on May 19, 2013